Funder: Alpha-1 Foundation
Due Dates: September 25, 2026 (LOI) | February 12, 2027 (Full application) | At least two months before meeting or travel (Sponsorship and travel requests)
Funding Amounts: Research: up to $200,000 over two years, or $400,000 for two-PI proposals; other awards up to $1,000–$300,000 by category
Summary: Supports basic, clinical, and ethical, legal, and social research to improve AAT deficiency treatment and care and advance a cure.
Key Information: Full research applications require an LOI invitation; pharmaceutical companies, biotechs, and industry cannot apply or collaborate.
Description
The Alpha-1 Foundation’s In-Cycle Grants Award Program supports research to improve the health of people with alpha-1 antitrypsin (AAT) deficiency, with the ultimate goal of finding a cure. It funds basic, translational, and clinical investigations into AAT expression, disease pathogenesis and management, and Alpha-1-related lung and liver disease. Ethical, legal, and social research addressing genetic conditions is also supported.
Research awards encourage novel, hypothesis-generating or hypothesis-testing work, including collaborations using a team science approach. Other categories support physician-scientist career development, postdoctoral training, pilot studies, and human-subject research testing new hypotheses or methods. Scientific meeting sponsorships and travel grants support relevant scientific gatherings, presentations of AAT-related research, and cross-training at established Alpha-1 laboratories.
